PostScript

LETTERS

Sonography as a replacement for sialography for the diagnosis of salivary glands affected by Sjögren's syndrome

Recently, it has been suggested that sonographic evaluation of the salivary glands is useful in the diagnosis of Sjögren's syndrome. Kawamura *et al* and, more recently, Arijji *et al*, showed that descriptive and quantitative assessment of the salivary glands by sonography efficiently differentiated between dis-

eased and normal glands in patients with Sjögren's syndrome.^{1,2} They showed that the proposed sonographic gradings correlated well with the sialographic gradings. These findings suggest that sonography might be an alternative diagnostic tool for Sjögren's syndrome.

Here, we attempted to determine whether sonography can take the place of sialography as an alternative technique for the assessment of salivary gland involvement in Sjögren's syndrome. Sialography and sonography were performed on 294 patients who presented with sicca syndrome (171 positive and 123 negative for Sjögren's syndrome). We diagnosed patients with Sjögren's syndrome on

the basis of the criteria of the European Community Study Group.³ Sonographic features characteristic of Sjögren's syndrome are heterogeneous echogenicity with hypo- and hyperechoic signals throughout the affected gland (fig 1).²

Table 1 shows the performance of each of the diagnostic criteria. Sialography performed best among the five diagnostic criteria—that is, sialography, functional tests (Saxon and Schirmer), and serological tests (SS-A and SS-B). Interestingly, when used instead of sialography, sonography provided a good performance, comparable with that of sialography (McNemar test, $p=0.067$).⁴ In contrast, the other diagnostic criteria did not perform as well as the two imaging criteria.

Logistic regression analysis was performed to identify diagnostic criteria that might be used as predictive indicators for differentiating between patients with and without Sjögren's syndrome.⁵ Univariate logistic regression analysis showed that the six diagnostic criteria assessed (sialography, sonography, Saxon's test, Schirmer test, SS-A, and SS-B) did correlate with a positive diagnosis of Sjögren's syndrome, indicating that these six criteria, if used alone, could effectively predict the presence of Sjögren's syndrome (table 1).

On multivariate analysis, however, only sialography and sonography showed significant correlations with a positive diagnosis of Sjögren's syndrome (table 1); when sialography was used together with the functional and serological criteria, only sialography showed a significant correlation. If sonography was used instead of sialography, only sonography displayed a significant correlation with a positive diagnosis of Sjögren's syndrome (table 1). Collectively, these findings suggest that the sonography performs as well as sialography in differentiating between parotid glands affected by Sjögren's syndrome and normal glands. In contrast, the other diagnostic criteria did not perform as well as the two imaging criteria.

Some discrepancies were found between the diagnostic performance in the present study and that in previous studies. For example, Schirmer's test in our study performed poorly compared with the performance reported by Vitali *et al*.³ SS-A and SS-B displayed high sensitivity and low specificity in our study, whereas low sensitivity and high specificity were found in the previous study.³ These inconsistencies may be due to the differences in patient groups or in techniques, or both. Despite these differences, the performance by sialography was similar, consistent with the notion that the imaging techniques, including sialography, provide reliable results in the diagnosis of Sjögren's syndrome.

In conclusion, a diagnosis of Sjögren's syndrome can be made on the basis of a wide range of diagnostic tests, and not merely on fixed combinations of these tests. Evaluation of salivary gland involvement contributes significantly to the performance of the criteria. Thus the availability of different imaging techniques, such as Doppler sonography⁶ and magnetic resonance imaging,⁷ to assess salivary gland involvement allows clinicians to classify patients with sicca syndrome correctly.

Figure 1 Sialography (A and B) and sonography (C and D) of the parotid glands in patients who presented with sicca syndrome (dry eyes and dry mouth). Normal glands (A and C), and glands affected by Sjögren's syndrome (B and D) are shown for comparison. Sialography of the parotid glands with Sjögren's syndrome shows characteristic globular (B) staining patterns. Sonography of the parotid glands with Sjögren's syndrome shows irregular echogenicity and multiple hyperechoic bands and hypoechoic areas in the gland (D).

Table 1 Performance and logistic regression analysis of diagnostic criteria for Sjögren's syndrome

	Sialography	Sonography	Saxon	Schirmer	SS-A	SS-B
Sensitivity (%)	87	76	70	59	83	88
Specificity (%)	98	94	71	57	56	42
Accuracy (%)	92	84	71	59	70	51
Univariate analysis						
Coefficient	6.02	3.69	1.67	0.56	1.92	1.66
SE	0.75	0.39	0.29	0.32	0.36	0.51
p Value	<0.00001	<0.00001	0.00006	0.00787	<0.00001	0.00012
Multivariate analysis						
Coefficient	4.87	3.97				
SE	1.06	1.07	NS	NS	NS	NS
p Value	<0.00001	0.00002				

NS, not significant.

K Yonetsu, Y Takagi, M Sumi,
T Nakamura

Department of Radiology and Cancer Biology,
Nagasaki University School of Dentistry, Japan

K Eguchi

First Department of Internal Medicine, Nagasaki
University School of Medicine, Japan

Correspondence to: Dr T Nakamura, Department of
Radiology and Cancer Biology, Nagasaki
University School of Dentistry, 1-7-1 Sakamoto,
Nagasaki 852-8588, Japan;
taku@net.nagasaki-u.ac.jp

References

- 1 Kawamura H, Taniguchi N, Itoh K, Kano S. Salivary gland echography in patients with Sjögren's syndrome. *Arthritis Rheum* 1990;33:505-10.
- 2 Arijji Y, Ohki M, Eguchi K, Izumi M, Arijji E, Mizokami A, *et al*. Texture analysis of sonographic features of the parotid gland in Sjögren's syndrome. *AJR Am J Roentgenol* 1996;166:935-41.
- 3 Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri A, Bencivelli W, Bernstein RM, *et al*. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. *Arthritis Rheum* 1993;36:340-7.
- 4 Dwyer AJ. Matchmaking and Mcnemar in the comparison of diagnostic modalities. *Radiology* 1991;178:328-30.
- 5 Chikui T, Yonetsu K, Nakamura T. Multivariate feature analysis of sonographic findings of metastatic cervical lymph nodes: contribution of blood flow features revealed by power Doppler sonography for predicting metastasis. *AJNR Am J Neuroradiol* 2000;21:561-7.
- 6 Chikui T, Yonetsu K, Izumi M, Eguchi K, Nakamura T. Abnormal blood flow to the submandibular glands of patients with Sjögren's syndrome: Doppler waveform analysis. *J Rheumatol* 2000;27:1222-8.
- 7 Izumi M, Eguchi K, Ohki M, Uetani M, Hayashi K, Kita M, *et al*. MR imaging of the parotid gland in Sjögren's syndrome: a proposal for new diagnostic criteria. *AJR Am J Roentgenol* 1996;166:1483-7.

Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment

Treatment with sulfasalazine has been reported to be effective in psoriatic arthritis (PsA).¹⁻³ However, the role of sulfasalazine in cutaneous lesions has been surrounded by controversies. As far as we know its possible beneficial effect on nail lesions has not been reported.

Case report

A 25 year old man had presented with nail lesions considered to be psoriatic since 1996. During the same period he started to have pain in both knee joints. Since 1998 he had also had pain in the distal interphalangeal (DIP) joints. At the end of the same year the patient consulted a rheumatologist. On clinical examination, both knee joints were swollen and a Baker's cyst was present at the right side. The 4th and 5th DIP joints of both hands were red, painful, and slightly swollen. Nail deformities were present in both hands (fig 1A) and feet. Psoriatic lesions of the auditory canals and intergluteal fold were seen, prompting the diagnosis of psoriasis psoriaticum.

Synovial fluid from the right knee joint contained 17.8×10^9 leucocytes/l (86% polymorphonuclear); no crystals were seen. The erythrocyte sedimentation rate was 33 mm/1st h. Rheumatoid factor was negative, as were cultures of nail specimens for fungi.

Radiographs of the hands and feet were normal. There were slight erosions of the sacroiliac joints and of the symphysis pubis.

The patient was treated with non-steroidal anti-inflammatory drugs (NSAIDs) and on several occasions with local injections of corticosteroids into the knee joints. For the psoriatic nails he took acitretine (Neotigason) at a daily dose of 20 mg, for 12 months, but the nail lesions did not improve. In view of the persisting arthritis, the patient has been treated since January 2000 with sulfasalazine (the dose being progressively increased from 0.5 g daily to 2 g daily), in addition to NSAIDs. Three months later, the nail lesions started to recede and they disappeared progressively (fig 1B); the improvement has persisted until now. Concomitantly, there was a marked improvement of the arthritis.

Discussion

Nail disease is significantly associated with PsA.⁴ It is particularly common in cases with DIP joint involvement and tends to indicate more severe PsA.⁵ In view of the close chronological relationship between the administration of sulfasalazine and the improvement of the nail lesions, it can be considered that sulfasalazine played a beneficial part in the pathological condition of our patient. Dermatological assessment of patients treated with sulfasalazine for PsA has been reported in two series; according to the report published in the series of Gupta *et al*, patients treated with sulfasalazine for PsA showed signs of cutaneous improvement compared with those receiving placebo.¹ The series of Farr *et al* reports improved cutaneous lesions in as few as 3/15 patients treated with sulfasalazine and 1/15 patients receiving placebo.² However, we could not find any indication of the evolution of possible simultaneous psoriatic nail lesions.

Treatment of PsA with cyclosporin or etanercept is effective for both joint and skin lesions of psoriasis^{6,7}; again no data about the outcome of psoriatic nail lesions were provided in these clinical studies. Our case report might be the occasion to draw the attention of rheumatologists to the possible beneficial effects of basic treatment such as sulfasalazine not only for PsA but also for treating psoriatic nails.

J C Gerster

Service de Rhumatologie, Médecine Physique et
Réhabilitation, Centre Hospitalier, Universitaire
Vaudois (CHUV), 1011 Lausanne, Switzerland;
Jean-Charles.Gerster@chuv.hospvd.ch

Figure 1 Left index finger (A) before, (B) after six months' treatment with sulfasalazine. The nail deformities in both hands are no longer present.

D Hohl

Service Universitaire de Dermatologie, CHUV,
1011 Lausanne, Switzerland

References

- 1 Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, *et al*. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. *J Rheumatol* 1995;22:894-8.
- 2 Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. *Br J Rheumatol* 1990;29:46-9.
- 3 Goupille P, Valat JP. Sulfasalazine: a definitively efficient treatment for psoriatic arthritis. *J Rheumatol* 1996;23:791-2.
- 4 Eastmond CJ, Wright V. The nail dystrophy of psoriatic arthritis. *Ann Rheum Dis* 1979;38:226-8.
- 5 Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. *Br J Rheumatol* 1994;33:834-9.
- 6 Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. *Ann Rheum Dis* 1990;49:603-6.
- 7 Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet* 2000;356:385-90.

Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease

The high cost of IV immunoglobulins is often considered to be a disadvantage of this treatment. However, this does not take into account the benefits gained—for example, the savings achieved in the costs of corticosteroids and immunosuppressive drugs and, above all, the improvement in quality of life achieved through functional improvement, as noticed in inflammatory myopathies and Still's disease.¹⁻³ It is precisely the costs of IV immunoglobulin treatments and to enable patients to remain at home that we have developed the administration of IV immunoglobulins at home when sequential treatments are necessary.

Between January 1995 and March 2000 30 patients (18 women, 12 men) were enrolled, with a mean (SD) age of 44 (0.9) for the women and 51 (0.9) years for the men (range 21-74). All the patients had received the first two treatments in hospital to ascertain their tolerance. Patients mostly received Tégéline (314 treatments), Endobuline (81 treatments), and Gammagard (three treatments). All the patients had a corticoid-dependent or refractory autoimmune disease (mostly polymyositis, dermatomyositis, and adult onset Still's disease).

The doses prescribed for each treatment were generally 2 g/kg. Treatments were carried out monthly and consisted of two days when performed in hospital and five days when performed at home. The average flow rate of the IV immunoglobulin perfusions performed at home was 10 g/2 h (extreme values: 30 min-4 h). The secondary effects of the treatments at home remained conventional and minor.

The efficacy of the IV immunoglobulin was described by the patients as very good 17%, good 33%, modest 3%, nil 47%. The efficacy of the IV immunoglobulin was described by the senior doctor as very good 53%, good 30%, nil 17%. Evaluation of the efficacy described by the patients themselves was based on purely functional criteria (general condition, pain,

Table 1 Evaluation of the cost of at home IV immunoglobulin treatments (n=277) and comparison with the theoretical cost in hospital

Mean costs for one treatment					
IV immunoglobulin	24 h hospital stay with hospital lump sum	Small equipment	Nursing	Total cost for 277 treatments	Savings achieved for 277 treatments
<i>Theoretical cost in hospital</i> \$2055 (deduction on drug budget)	\$605	\$41 (deduction on small equipment budget)	0	\$748274	\$580556 (representing the virtual economy made by the hospital department (drug budget + small equipment))
Cost for one treatment in hospital : \$2701					
<i>Effective cost at home</i> \$2363 (15% of retrocession overcost*)	0	\$41	\$67	\$684588	<ul style="list-style-type: none"> • \$63691 (representing the effective savings for the community) • \$85377 (representing the budget income for the hospital administration)
Cost for one treatment at home: \$2471					

*In France when a drug is retroceded by a hospital pharmacy, it is invoiced 15% higher, the difference being paid to the hospital administration to cover the management and traceability costs.

muscular deficit, etc), which explains the difference between the two evaluations. Cases where the IV immunoglobulin resulted in a reduced use of corticosteroids, or cases where IV immunoglobulins made it possible to avoid using immunosuppressive drugs were regarded as a success by the senior doctor, whereas patients did not necessarily have the same impression.

The 23 patients (77%) who said they had benefited from the IV immunoglobulin treatments at home gave the following reasons: better comfort (n=12), presence of next of kin (n=10), more occupation (n=6), time gain (n=5), better mood (n=3), maintaining activities (n=3), avoiding repeated trips to the hospital (n=3), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital gave the following reasons: better monitoring, less trouble (IV immunoglobulin collected at the hospital pharmacy, calling the nurse at home, collection of tubes, needles, and perfusion stand at the pharmacy and at home).

The mean cost of a treatment in hospital was \$2701 against \$2471 for a treatment at home. The difference seems to be modest, yet for the 277 treatments performed at home over five years, the savings for the community amount to \$63 691 with \$85 377 of budget revenues for the hospital (the 15% increase is in fact invoiced by the hospital administration for

management and traceability costs). By this procedure, we have achieved a virtual economy on our drug budget and small equipment of \$580 556 in the past five years (table 1).

In the light of our experience and published reports of side effects,⁴⁻⁸ we propose some guidelines for home IV immunoglobulin infusion for patients with autoimmune disease (table 2). This procedure is appreciated by the patients and medical board and contributes to balancing the expenses for the National Health System.

Acknowledgments

To Monique Tomczak who typed this document; Thomas Rémy, Bernard Dauvergne, and Mazen Elzaabi (Laboratoire français du fractionnement et des biotechnologies, 3 avenue des Tropiques, BP 305, Les Ulis, 91958 Courtaboeuf cedex) who helped us with the technical aspect of this study.

E Hachulla, A Wibaux, P-Y Hatron, U Michon-Pasturel, V Queyrel, A-L Fauchais, B Devulder

Internal Medicine Department, Hôpital Claude Huriez, University of Lille, 59037 Lille cedex, France

M-N Lefebvre, M Yilmaz

Central Pharmacy, University of Lille

Correspondence to: Professor E Hachulla, Internal Medicine Department, Hôpital Claude Huriez, University of Lille, 59037 Lille cedex, France; ehachulla@chru-lille.fr

References

- 1 Chérin P, Herson S, Wechsler B, Piette JC, Bléry O, Coutelier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. *Am J Med* 1991;91:162-8.
- 2 Chérin P, Piette JC, Wechsler B, Bléry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. *J Rheumatol* 1994;21:1092-7.
- 3 Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC. Traitement de la maladie de Still de l'adulte par immunoglobulines intraveineuses. *Rev Med Interne* 1995;16:250-4.
- 4 Elkayam O, Paran D, Milo R, Davidovitz Y, Almozino-Sarafian D, Zeltser D, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. *Ann Rheum Dis* 2000;59:77-80.
- 5 Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? *Eur Neurol* 1999;41:153-8.
- 6 Chatot-Henry C, Smadja D, Mehdaoui H, Fournier P, Draut JN, Brebion A, et al. Insuffisance rénale aiguë et infarctus cérébral au cours d'un traitement par immunoglobulines intraveineuses à fortes doses. *Rev Med Interne* 1998;19:914-16.
- 7 Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. *Lancet* 1992;14:662-4.
- 8 Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. *Mayo Clin Proc* 2000;75:83-5.

Elastofibroma dorsi

Elastofibroma is a rarely diagnosed benign fibroproliferative lesion which occurs most commonly in the periscapular region of middle aged to elderly women.¹ Recognition of the lesion is important as the differential diagnosis includes other benign and also

Table 2 Home IV immunoglobulin infusion guidelines for patients with autoimmune disease

1.	Need for a defined diagnosis
2.	Presence of rational physiopathological basis that could "legitimise" the use of IV immunoglobulin
3.	Senior hospital prescription
4.	Respect of the contraindication of home IV immunoglobulin programme: coronaropathy, insufficiency or ischaemic cardiopathy, recent stroke, nephropathy, uncontrolled hypertension, thrombosis of the perfused vein; hypersensitivity reaction after the first or second hospital infusion
5.	More than one hospital based infusion before infusion at home to assess the tolerance
6.	Average flow rate of IV immunoglobulin no quicker than 10 g per two hours
7.	Collaboration with a home care organisation for visiting nurses and for collection of tubing and used bottles

Figure 1 Magnetic resonance image (T₁ weighted axial) of the right infrascapular region showing a poorly defined mass (long arrow) with areas of high signal within. The mass lies between the serratus anterior (short arrow) and the thoracic cage (C). L, latissimus dorsi.

malignant tumours. We report a case of elastofibroma in a patient who presented with shoulder pain to a rheumatology clinic, and review previous publications. Although elastofibroma is uncommon, it has received attention in radiological and orthopaedic publications but not in rheumatology published reports.

A 43 year old Turkish woman, previously fit and healthy, was referred to our outpatient clinic with a two year history of right shoulder pain. The pain was described as a dull ache of gradual onset, around the posterior aspect of the shoulder over the scapula, which was worse on movement of the arm. There was no weakness. Over the preceding four months the patient had noticed a swelling below the inferior angle of the right scapula which would appear and disappear with movement of the arm. The patient had no other medical history or relevant family history.

On examination there was a full range of movement of both shoulders and neck with no wasting or neurological signs. Pain was reproduced around the right shoulder when the arm was circumducted. In this position a firm, poorly circumscribed, and minimally mobile mass of 5x5 cm was apparent underlying the inferior angle of the scapula. The rest of the examination was normal.

Initial investigations showed a normal full blood count, bone profile, and inflammatory markers, and a normal radiograph of the right shoulder and scapula. Subsequent magnetic resonance imaging (MRI) showed a poorly circumscribed heterogeneous soft tissue mass between the chest wall and the scapula (fig 1). The signal intensity was similar to that of adjacent muscles with interspersed strands of high signals similar to those of fat. No significant contrast enhancement was seen. The lesion was biopsied under computed tomography guidance and a histological examination showed elastic fibres within a collagenous fibrous tissue with entrapped adipose tissue, consistent with a diagnosis of elastofibroma. Surgical excision was performed

because the mass was causing pain. Postoperative histology confirmed an elastofibroma. The patient has remained asymptomatic after surgery with no recurrence of the mass.

Elastofibroma dorsi, first described in 1961,² is a benign, slow growing, mesenchymal soft tissue lesion.³ They usually occur in active subjects above the age of 50 with a male:female ratio of 1:5.⁴ Most (99%) occur in the subscapular region, usually on the right side. The lesions have occasionally been found in the extremities, head, abdominal and thoracic cavities.⁵ Of those in the subscapular region approximately 10% are bilateral.⁵ The cause and pathogenesis are unclear, but it is suspected that subclinical microtrauma may lead to reactive hyperplasia of elastic fibres with consequently increased production of fibrous tissue.⁶ Clinically, over 50% of subjects are asymptomatic and may present with a painless swelling; approximately 25% present with a clicking sensation when the arm is moved, while fewer than 10% present with pain.⁷

Plain radiographs may be normal or may show soft tissue density in the periscapular region when the scapula is raised.³ Computed tomography usually shows a heterogeneous soft tissue mass with poorly defined margins.³ MRI is the best non-invasive technique and most useful for diagnosis. Elastofibromas appear as poorly circumscribed soft tissue lesions with similar signal intensity to that of skeletal muscle but interspersed with high signal intensity areas representing adipose strands.⁸ The differential diagnosis includes desmoid tumours, neurofibroma, and liposarcoma. However, these tumours usually show strong enhancement after gadolinium injection. Usually faint enhancement is seen with elastofibromas, although marked enhancement, mimicking malignant tumour, has been occasionally reported.⁹ Biopsy should therefore be undertaken as the confirmatory procedure and to exclude sarcoma.

In cases where the patient is asymptomatic excision is unnecessary. Malignant transformation is unknown. In symptomatic cases

local excision is the best treatment.¹⁰ Recurrence has not been reported.

We conclude that elastofibroma should be considered in the differential diagnosis of subscapular pain. Although an uncommon lesion with a variable clinical presentation, the site and MRI appearances are characteristic. Awareness of the benign nature avoids unnecessary surgery and reassures a symptomatic patient.

D Pyne, R Mootoo, A Bhanji

Rheumatology Department, Homerton Hospital, Homerton Row, London E9 6SR, UK

S Amin

Radiology Department, Homerton Hospital

Correspondence to: Dr R Mootoo

References

- 1 Simcock DE, Gilmour AM, Sallomi DF. Elastofibroma dorsi: a rare tumour. *Hosp Med* 1998;59:894-5.
- 2 Jarvi OH, Saxen AE. Elastofibroma dorsi. *Acta Pathol Microbiol Scand* 1961;144(suppl 51):83-4.
- 3 Giebel GD, Bierhoff E, Vogel J. Elastofibroma and pre-elastofibroma- a biopsy and autopsy study. *Eur J Surg Oncol* 1996;22:93-6.
- 4 Nielsen T, Sneppen O, Myhre-Jensen O, Daugaard S, Norbaek J. Subscapular elastofibroma: a reactive pseudotumour. *J Shoulder Elbow Surg* 1996;5:209-13.
- 5 Hoffman JK, Klein MH, McInerney VK. Bilateral elastofibroma: a case report and review of the literature. *Clin Orthop* 1996;325:245-50.
- 6 Machens HG, Meckertshiemer R, Gohring U, Schlag PN. Bilateral elastofibroma dorsi. *Ann Thorac Surg* 1992;54:774-6.
- 7 Greenberg JA, Lockwood RC. Elastofibroma dorsi: a case report and review of the literature. *Orthop Rev* 1989;18:329-33.
- 8 Soler R, Requejo I, Pombo F, Saez A. Elastofibroma dorsi: MR and CT findings. *Eur J Radiol* 1998;27:264-7.
- 9 Zembsch A, Schick S, Trattig S, Walter J, Amann G, Ritschl P. Elastofibroma dorsi. Study of two cases and magnetic imaging findings. *Clin Orthop* 1999;364:213-19.
- 10 Briccoli A, Casadei R, Di Renzo M, Favale L, Bacchini P, Bertoni F. Elastofibroma dorsi. *Surg Today* 2000;30:147-52.

Olecranon bursitis due to *Candida parapsilosis* in an immunocompetent adult

Septic bursitis (SB) mainly affects the olecranon and patellar bursae. Subcutaneous localisation predisposes to trauma and may subsequently lead to infection. Most cases of SB are related to the subject's occupation (roofing, gardening, plumbing), but surgical interventions (aspiration, intrabursal injection) are among other probable causes.¹ Bacteria account for most cases, *Staphylococcus aureus* being the most commonly found (80%).^{1,2} Fungal isolation is quite rare and always associated with immunosuppression or debilitating conditions,³ but some species of *Candida*, *Cryptococcus*, *Penicillium*, and *Sporothrix schenckii* have been described.¹ These atypical organisms usually develop in a late indolent pattern, and a delay in diagnosis and treatment may lead to considerable difficulties in eradication of infection. We report a case of SB caused by *Candida parapsilosis* in a previously healthy man, with no underlying disease or any risk factors, including HIV infection, who probably acquired joint infection at the hospital secondary to local steroid injection.

Case report

A 32 year old man with a one month history of mild inflammation of the right elbow presented to our hospital on 19 May 2000. He had

Table 1 Main clinical features of candida bursitis

Case [ref]	Age/sex	Candida strains	Localisation	Underlying disease/ risk factors	Probable source	Treatment	Outcome
1 [3]	73/M	<i>C albicans</i>	Subacromial	SLE/steroids	Candidaemia	AMB	Cure
2 [5]	77/M	<i>C tropicalis</i>	Olecranon	Bladder carcinoma	Candidaemia	AMB + bursectomy	Cure
3 [6]	48/M	<i>C tropicalis</i>	Popliteal	Lymphoma/ immunosuppressive drugs	Candidaemia	AMB + surgery	Cure
4 [7]	64/M	<i>C albicans</i>	Popliteal	Alcoholism/steroids, antibiotics	Candidaemia	AMB; ketoconazole	Cure
5 [8]	59/F	<i>C lusitanae</i>	Olecranon	SLE, diabetes, asthma/ steroids, immunosuppressive drugs	Superficial trauma (Lunger's elbow)	Fluconazole; 5-FC	Failure
6 [CR]	32/M	<i>C parapsilosis</i>	Olecranon	None	Steroid injection	Fluconazole + bursectomy	Cure

CR, current report; AMB, amphotericin B; SLE, systemic lupus erythematosus; 5-FC, 5-fluorocytosine.

an unremarkable past medical history, which did not include any toxic habits or recent trauma. Bursal aspiration showed that the synovial fluid had inflammatory characteristics (leucocyte count 4.9×10^9 cells/l (54% neutrophils), and a glucose level of 3.8 mmol/l), but there were no crystals and a fluid culture was negative. A diagnosis of olecranon bursitis was established, and conservative management (fluid aspiration) was decided on. Bursal effusion was repeated over the next four days, so a further aspiration was carried out and local injection with triamcinolone acetate (20 mg) was given. However 24 days later the pain worsened and swelling of the elbow recurred; laboratory synovial findings showed a leucocyte count of 15.7×10^9 cells/l (60% neutrophils) and a low glucose level (0.8 mmol/l). Culture yielded a few colonies of *Candida* spp, but antifungal treatment was not started because it was considered that this might be caused by contamination. One month later (28 July), the patient presented to the emergency room owing to development of a new extremely painful episode of bursitis. After joint aspiration, a steroid injection was again given, but this time a fluid culture was not carried out.

On 1 August clinical symptoms persisted. Physical examination showed an increase in the size of the olecranon bursa. The patient had never presented with fever, arthralgias, or any general complaints. Laboratory studies, including a test for antibodies to HIV, were normal or negative. Magnetic resonance imaging was performed showing multiseptate bursitis; the adjacent structures were normal. A removal of 10 ml bursa fluid again yielded a positive culture for *Candida* that was later identified as *C parapsilosis* (Majadahonda (Madrid), National Centre for Microbiology). Antifungal sensitivity testing showed a minimal inhibitory concentration for amphotericin B of 1 mg/l, 5-fluorocytosine 0.25 mg/l, fluconazole 0.25 mg/l, itraconazole 0.03 mg/l, and ketoconazole 0.015 mg/l. By the end of August, oral fluconazole was started at a dose of 400 mg/day for seven days, and then 200 mg daily. Recovery was slow and the patient needed repeated drainage. As follow up cultures were still positive, on 27 September it was decided to carry out surgical debridement with complete excision of the olecranon bursa. This material was not cultured, but histopathological analysis was performed demonstrating pseudohyphae structures, without granulomatous reaction or foreign bodies. After bursectomy, the patient continued fluconazole treatment (same maintenance dose) for six weeks more. Six months later he is completely asymptomatic.

Infection of superficial bursae (olecranon, prepatellar, and infrapatellar) is generally associated with different occupations or

physical activities. Local trauma may predispose micro-organisms to penetrate by the transcutaneous route.¹ Similarly, intrabursal steroid injection, a habitual therapeutic procedure, may lead to infection. Weinstein *et al* noted that development of infection after this procedure occurred in 12% of a series of cases.⁴ Most frequently bacteria cause infections, but unusual pathogens like fungi have also been described.¹ *Candida* septic bursitis is extremely rare. After a thorough review of the Medline database (from 1966 to January 2001) using medical subject headings, and keyword searches that included "septic bursitis" and "*Candida*", we found only five reports.³⁻⁸ Two caused by *C albicans*, two by *C tropicalis*, and another one by *C lusitanae* (table 1). Characteristically, in all the cases, and in the present report, different risk factors or underlying diseases were found. Four cases were caused by haematogenous spread and two induced by direct penetration, including our case. The olecranon bursa was affected in three cases, including the present report.

C parapsilosis is a well known cause of arthritis that has been described secondary to systemic dissemination in intravenous drug users,⁹ and also by direct inoculation secondary to catheterisations¹⁰ or intra-articular injections.⁷ It is not strongly associated with immunocompromised hosts, but rather with invasive procedures or prosthetic devices.¹¹ More recently *C parapsilosis* has emerged as an important nosocomial pathogen. This is the *Candida* species that is most commonly isolated from the hands of healthcare workers.¹² In contrast with other *Candida* species, colonisation with *C parapsilosis* rarely occurs before the onset of invasive infection, suggesting an exogenous source of infection.

Appropriate antifungal drugs to treat *Candida* infections are available, but appropriate drug levels in osteoarticular structures are difficult to achieve. So for successful treatment of this infection, surgery is sometimes required. Half of the patients with *Candida* SB reviewed needed surgery for complete resolution (table 1).

We would like to summarise several aspects of the present report: Firstly, steroid injection must be carefully prescribed in order to avoid probable side effects like infection.⁴ Secondly, most cases of *Candida* SB are produced by haematogenic spread, secondary to disseminated infection, whereas the present case was almost certainly through direct inoculation. Thirdly, isolation of *C parapsilosis* was neglected at the start so that antifungal treatment was delayed, leading to the need for surgery. We consider that the diagnostic delay together with a rather low maintenance dose of fluconazole were critical for the very slow resolution of the infection; probably 400

mg/day would have been more suitable for an infection in a deep compartment.

Because unusual micro-organisms are difficult to recognise and anti-inflammatory drugs may mask the symptoms, a higher degree of awareness is necessary to achieve prompt diagnosis and successful treatment. Nevertheless, special care must be taken to avoid complicating side effects in iatrogenic manipulations, so preventive measures to reduce the incidence of infection must never be omitted.

M Jiménez-Palop, M Corteguera

Unit of Rheumatology, Hospital Nuestra Señora de Sonsoles, Avila, Spain

R Ibáñez

Unit of Microbiology, Hospital Nuestra Señora de Sonsoles

R Serrano-Heranz

Unit of Infectious Diseases, Hospital Nuestra Señora de Sonsoles

Correspondence to: Dr R Serrano-Heranz, Encarnación 14, Chalet 18, 05005 Avila, Spain; reginosh@interbook.net

References

- Zimmermann B 3rd, Mikolich DJ, Ho G Jr. Septic bursitis. *Semin Arthritis Rheum* 1995;24:391-410.
- Canoso JJ, Barza M. Soft tissue infections. *Rheum Dis Clin North Am* 1993;19:293-309.
- Roschmann RA, Bell CL. Septic bursitis in immunocompromised patients. *Am J Med* 1987;83:661-5.
- Weinstein PS, Canoso JJ, Wohlgethan JR. Long-term follow-up of corticosteroid injection for traumatic olecranon bursitis. *Ann Rheum Dis* 1984;43:44-6.
- Murray HW, Fialk MA, Roberts RB. Candida arthritis. A manifestation of disseminated candidiasis. *Am J Med* 1976;60:587-95.
- Wall BA, Weinblatt ME, Darnall JT, Muss H. Candida tropicalis arthritis and bursitis. *JAMA* 1982;248:1098-9.
- Cuende E, Barbadillo C, E-Mazzucchi R, Isasi C, Trujillo A, Andreu JL. Candida arthritis in adult patients who are not intravenous drug addicts: report of three cases and review of the literature. *Semin Arthritis Rheum* 1993;22:224-41.
- Behar SM, Chertow GM. Olecranon bursitis caused by infection with *Candida lusitanae*. *J Rheumatol* 1998;25:598-600.
- Yarchoan R, Davies SF, Fried J, Mahowald ML. Isolated *Candida parapsilosis* arthritis in a heroin addict. *J Rheumatol* 1979;6:447-50.
- De Clerck L, Dequeker J, Westhovens R, Hauglustaine D. Candida parapsilosis in a patient receiving chronic hemodialysis. *J Rheumatol* 1988;15:372-4.
- Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. *Clin Infect Dis* 1992;14:756-66.

- 12 Huang YC, Lin TY, Leu HS, Wu JL, Wu JH. Yeast carriage on hands of hospital personnel working in intensive care units. *J Hosp Infect* 1998;39:47–51.

Prevalence of allergic respiratory diseases in patients with RA

The balance between Th1 and Th2 cell activity is considered crucial in many autoimmune disorders.^{1,2} It has been suggested that rheumatoid arthritis (RA) is T1 cell predominated,³ whereas atopic diseases are T2 cell directed.⁴ Some recent observations^{5,6} of a decreased prevalence of atopy in patients with RA have received a lot of attention.⁷ It has been suggested that a T2 cell related disorder such as atopy might have a protective role against the onset of a T1 cell mediated disease such as RA,⁸ and the biological importance of the Th1/Th2 paradigm has been emphasised.

We evaluated the prevalence of atopic respiratory diseases in 126 consecutively observed outpatients with RA (diagnosed according to the American College of Rheumatology (ACR) criteria). The presence of allergic respiratory diseases was investigated in all patients by an exhaustive interview and the administration of skin prick tests by a trained allergologist. Skin prick tests were made according to the EAACI guidelines,⁹ with a panel including the most common airborne allergens of our area. A diagnosis of allergic rhinitis was made in 21 patients (16.6%). The diagnosis was based on a suggestive clinical picture associated with the positivity of skin prick tests. Seven of 21 patients also had symptoms of asthma and 3/21 had undergone specific immunotherapy before the onset of RA symptoms. In 20/21 patients allergic respiratory symptoms had started before the onset of RA symptoms. In 5/21 patients atopic symptoms had totally disappeared by the time of this study.

Patients with RA with associated atopic disease did not differ from other patients with RA in the following characteristics: (a) sex (76.2% female v 75.2%); (b) positivity of rheumatoid factor (71.4% v 63.8%); (c) presence of subcutaneous noduli and/or other extra-articular manifestations (14.3% v 21.9%); (d) functional class according to the ACR revised criteria (class I-II: 64% v 60%); (e) current treatment with two or more disease modifying antirheumatic drugs in combination (57.1% v 60.9%); (f) current steroid treatment (57.1% v 54.3%). Notably, most patients from both groups (90.9% v 76.8%) were taking steroids at a low dose—namely, not more than 5 mg daily of prednisone, when they were evaluated for this study.

Patients with atopic diseases were younger (mean age 53.8 v 57.5) and had a shorter average duration of RA (4.5 v 9.7 years) than those without.

We found a rather high prevalence of allergic respiratory diseases in our patients with RA (16.6%), comparable with that expected in the general population.¹⁰ Moreover, the presence of atopic disease did not seem to influence the severity of RA.

The difference between our data and other reports^{5,6} may be due to the methods used to determine the presence of atopic diseases. Those other studies started from the administration of standardised questionnaires to patients with RA and this method might have caused an underestimation of atopic symptoms. Conceivably, prolonged steroid treatment, as well as the systemic symptoms and disability associated with RA, may often cause occult symptoms of rhinitis and asthma that only emerge at deeper analysis.

In conclusion, our data question the hypothesis of a mutual antagonism of RA and atopy, suggesting caution in interpreting previous data and confirming that things are often not as simple as they can seem at first glance.

G Provenzano, G Donato

Azienda Ospedaliera "Villa Sofia – CTO",
Divisione di Malattie dell'Apparato Respiratorio,
Palermo, Italy

G Brai, F Rinaldi

Azienda Ospedaliera "V. Cervello", Divisione di
Medicina II, Palermo, Italy

Correspondence to: Dr G Provenzano, Via
Massimo d'Azeglio No 2, 90143 Palermo, Italy;
giuseppe.provenzano5@tin.it

References

- 1 Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. *Arthritis Rheum* 1992;35:729–35.
- 2 Romagnani S. Biology of human Th1 and Th2 cells. *J Clin Immunol* 1995;5:121–9.
- 3 Dolhain RJE, Van Der Heiden AN, Ten Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. *Arthritis Rheum* 1996;39:1961–9.
- 4 Del Prete G. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. *Allergy* 1992;47:450–5.
- 5 Verhoef CM, van Roon JAG, Vianen ME, Bruijnzeel-Koomen CAFM, Lafeber FPJG, Bijlsma JWW. Mutual antagonism of rheumatoid arthritis and hay fever; a role for type1/type2 T cell balance. *Ann Rheum Dis* 1998;57:275–80.
- 6 Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ. Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. *Rheumatology (Oxford)* 2000;39:1020–6.
- 7 Anonymous. *The Times* 1998 Aug 3, page 80.
- 8 Gaston JSH. Will the increasing prevalence of atopy have a favourable impact on rheumatoid arthritis? *Ann Rheum Dis* 1998;57:265–7.
- 9 Dreborg S, Backman A, Basomba A, et al. Skin tests used in type 1 allergy testing. Position paper of the European Academy of Allergy and Clinical Immunology. *Allergy* 1989;44(suppl 10):1–59.
- 10 Schafer T, Ring J. Epidemiology of allergic diseases. *Allergy* 1997;52(suppl 38):14–22.

Henoch-Schönlein purpura: a possible complication of hepatitis C related liver cirrhosis

Henoch-Schönlein purpura (HSP) is a systemic small vessel vasculitis predominantly affecting children and, less commonly, adults. Classical HSP includes a tetrad of palpable purpura, arthritis, abdominal pain, and glomerulonephritis. Adults may present with any two of the four criteria in the tetrad (87% sensitivity and specificity). Gastrointestinal disease has been recorded in up to 82% of adult patients in one series¹ and is usually self limiting with colicky abdominal pain, but may progress to ischaemic bowel perforation.²

We present the case of a 63 year old man with IgA vasculitis, probably HSP, confounded by undiagnosed hepatitis C related cirrhosis.

He was admitted with a two week history of dyspnoea, malaise, cough, fevers, and chills, myalgias, one day of a non-blanching erythematous rash on his legs, and an ileus. His hepatitis C antibody was positive; table 1 shows the results of other laboratory studies.

Cultures of cerebrospinal fluid, blood, and urine were negative. A colonoscopy was non-diagnostic.

Leucocytoclastic vasculitis was confirmed by skin biopsy, and direct immunofluorescence staining was positive for IgA deposits consistent with HSP (fig 1).

Treatment with high dose (1 mg/kg/day) intravenous corticosteroids was started. A computed tomographic (CT) scan of the abdomen showed portal hypertension, a small cirrhotic liver, small spleen, omental and perisplenic varices, an atrophic pancreas, and modest ascites. The purpuric lesions and ileus improved; however, on day 4 he became tachycardic and developed a tender abdomen. A second CT scan showed massive ascites, a partial superior mesenteric vein thrombosis, thickening, and focal and nodular irregularities throughout the small bowel (probable ischaemia), and pneumoperitoneum. Blood cultures disclosed septicemia with *Bacteroides fragilis*. His clinical course rapidly deteriorated and he died on day 8.

There are two previous case reports of the association between HSP and hepatitis C.^{3,4} The diagnosis of HSP in our patient is most likely, given palpable purpura, haematuria, abdominal pain, and a skin biopsy demonstrating IgA complexes (fig 1). However, the possibility of hepatitis C associated IgA/IgM mixed cryoglobulinaemia cannot be ruled out despite a negative cryoglobulin screen⁵ on two occasions. In this patient an IgA mediated vasculitis may have been the nidus for thrombus formation and abdominal catastrophe.

The role of liver cirrhosis in the development of HSP is intriguing. Patients with cirrhosis may develop HSP as a consequence of defective liver metabolism of IgA circulating immune complexes (CICs), resulting in tissue deposition, although this is known to occur without overt vasculitis.⁶

Adult and paediatric HSP differ in the incidence and severity of renal involvement, with nephropathy and progression to renal insufficiency being greater in adult HSP⁷ which is associated with a poor outcome.⁸ Gastrointestinal manifestations vary widely and include abdominal pain, nausea/vomiting, intestinal haemorrhage and, rarely, perforation.

There have been no large clinical trials in adults with complicated HSP. Corticosteroids used in a series of children have been shown to relieve symptoms,⁹ but fail to deal prospectively with the prevention of abdominal complications. Adults respond favourably to corticosteroids and may be managed with short courses of treatment,¹⁰ but corticosteroids may also mask severe abdominal catastrophe.

Several important points can be learnt from this case report:

- Although nephritis is the most important long term prognostic factor in HSP, in the short term, gastrointestinal disease can lead to death despite early therapeutic intervention
- Liver cirrhosis secondary to hepatitis C may precipitate development of HSP or mixed cryoglobulinaemic vasculitis through the defective metabolism of CICs
- Given the increasing incidence of hepatitis C related liver disease world wide, the association of these diagnoses and their clinical implications should be considered more often.

Acknowledgments

We thank Drs Karen Stout, Brett Sheppard, Amy Howard, and Sandhya Venugopal for their participation in, and discussions about, this case.

Table 1 Significant laboratory values on the day of admission

Study	Patient's values	Normal values
Haemoglobin (g/l)	114	135–175
White blood cell count ($\times 10^9$ /l)	14000	3.4–10
Platelet count ($\times 10^9$ /l)	130	0.15–420
Complement C3 (mg/l)	400	880–2030
Complement C4 (mg/l)	<100	160–470
Serum creatinine (μ mol/l)	88	70–110
Alkaline phosphatase (U/l)	99	35–105
Aspartate aminotransferase (U/l)	40	11–32
Alanine aminotransferase (U/l)	39	5–30
Lactate dehydrogenase (U/l)	176	110–205
Total bilirubin (μ mol/l)	38	4–20
Albumin (g/l)	15	36–52
Urine analysis (RBC/HPF)	20	0–3
ANA titre	1/40	<1/40

RBC/HPF, red blood cells/high power field; ANA, antinuclear antibody.

Figure 1 Immunofluorescence staining of a skin biopsy from a purpuric lesion. Direct immunofluorescence study showing granular deposition of IgA in the walls of superficial dermal blood vessels, a characteristic finding in Henoch-Schönlein purpura.

D L Madison

Department of Medicine, Division of Endocrinology and Metabolism, Oregon Health Sciences University, Portland OR 97201, USA

E Allen, A Deodhar

Department of Medicine, Division of Arthritis and Rheumatological Disease, Oregon Health Sciences University

L Morrison

Department of Medicine, Division of Dermatology, Oregon Health Sciences University

Correspondence to: Dr Madison; madisond@ohsu.edu

References

- 1 **García-Porrúa C**, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. *Semin Arthritis Rheum* 1999;28:404–12.
- 2 **Chan JCN**, Li PKT, Lai FM, Lai KN. Fatal adult Henoch-Schönlein purpura due to small intestinal infarction. *J Intern Med* 1992;232:181–4.

- 3 **Frankum B**, Katelaris CH. Hepatitis C infection and Henoch-Schönlein purpura. *Aust NZ J Med* 1995;25:176.
- 4 **Gharavi AE**, Patel BM, Hughes GR, Elkan KB. Common IgA and IgM rheumatoid factor idiotypes in autoimmune disease. *Ann Rheum Dis* 1985;44:155–8.
- 5 **Ogawa M**, Makino Y, Ueda S, Ohto M, Akikusa B. Rapidly progressive glomerulonephritis in association with Henoch-Schönlein purpura in a patient with advanced liver cirrhosis. *Nephron* 1995;71:365–6.
- 6 **Aggarwal M**, Manske CL, Lynch PJ, Paller MS. Henoch-Schönlein vasculitis as a manifestation of IgA-associated disease in cirrhosis. *Am J Kidney Dis* 1992;20:400–2.
- 7 **Blanco R**, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M, Gonzalez-Gay MA. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. *Arthritis Rheum* 1997;40:859–64.
- 8 **Fogazzi GB**, Pasquali S, Moriggi M, Casanova S, Damilano I, Mihatsch MJ, *et al*. Long-term outcome of Schönlein-Henoch nephritis in the adult. *Clin Nephrol* 1989;31:60–6.
- 9 **Rosenblum ND**, Winter HS. Steroid effects on the course of abdominal pain in children with HSP. *Pediatrics* 1987;79:1018–21.
- 10 **Szer I**. Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Schönlein purpura. *Cleve Clin J Med* 1999;66:312–17.

Severe aortic regurgitation in RF positive polyarticular JIA

An 18 year old girl of Moroccan origin with a clear medical history was transferred to the Netherlands in February 1989 because of a two year history of untreated polyarthritis. The disease had pursued a rapidly destructive course, resulting in contractures and ankylosis of hips, knees, shoulders, and elbows and small joint deformation. A diagnosis of juvenile idiopathic arthritis (JIA) polyarticular type, functional class IV was made. No nodules were present. Laboratory analysis at that time showed borderline positive serum rheumatoid factor (RF) 30 IE/ml. Tests for antinuclear antibodies and HLA-B27 were negative. Treatment was started with intensive physiotherapy and intramuscular gold, the latter being replaced by sulfasalazine because of proteinuria. In 1990 she was treated for a unilateral uveitis. In 1992 her right elbow was replaced. Until 1993 cardiac examination showed no murmurs and chest roentgenogram was normal.

In November 1995 she was admitted because of a six month history of progressive

respiratory distress and increasingly frequent attacks of angina pectoris. Her heart rate was 84 beats/min with a blood pressure of 160/0 mm Hg. A grade 3/6 systolic ejection murmur that radiated into the ascending aorta was heard over the cardiac apex as well as a grade 3/6 early diastolic decrescendo murmur over the left sternal border. A pericardial friction rub was not present. Examination of the carotid arteries disclosed a murmur and palpable thrill on both sides. An electrocardiogram showed left ventricular hypertrophy and the chest radiograph slight cardiomegaly. An echocardiogram demonstrated left ventricular dilatation (65 mm; normally <55 mm) and an abnormally thickened aortic valve. Colour Doppler echocardiography showed severe aortic regurgitation, a pressure gradient over the aortic valve (maximum pressure gradient 38 mm Hg, mean gradient 24 mm Hg), and diastolic back flow in the abdominal aorta. The diagnosis aortic valve insufficiency and secondary angina pectoris was made.

She underwent surgical replacement of her aortic valve with a Medtronic Hall prosthetic valve No 21. The postoperative course was uneventful. Pathological evaluation of the excised strongly thickened and fibrotic tri-leaflet aortic valve was performed.

Microscopic findings in one of the rheumatoid leaflets showed granulation tissue with lymphoplasmocellular infiltration and some polymorphonuclear cells around two areas of fibrinoid necrosis surrounded by a palisade of histiocytes (figs 1 and 2). These findings are similar to the description of a developed typical rheumatoid nodule.¹

At follow up after four years the aortic valve prosthesis still functions well and the patient has no cardiac signs and symptoms.

To our knowledge, this case is the first illustrated report of typical rheumatoid nodules found in an aortic valve removed owing to aortic valve insufficiency in a patient with polyarticular JIA. Our patient never had any nodules on other locations. Valvular disease is rare in patients with JIA² and consists of valvulitis with a substrate with non-specific

Figure 1 Section from aortic valve cusp showing a central area of fibrinoid necrosis (a), a palisade of radially arranged histiocytes (b), and a lymphoplasmocytic infiltrate (c) (haematoxylin and eosin). Bar represents 400 μ m.

Figure 2 Detail of an area of fibrinoid necrosis surrounded by a palisade of histiocytes; infiltration predominantly with lymphocytes and plasma cells (haematoxylin and eosin). Bar represents 25 μ m.

changes of fibrosis and necrosis. Valvular involvement has been described in patients with all types of JIA,³ the aortic valve being most commonly affected.⁴⁻⁹ Valvular disease is associated with severe destructive articular disease.⁴⁻⁷

Furthermore, our case report confirms the possibility of successful mechanical aortic valve replacement in a case of severe progressive aortic valve insufficiency and secondary angina pectoris in a patient with polyarticular JIA.

We recommend regular cardiac appraisal as part of the routine assessment of every patient with JIA. Whenever cardiac murmurs are detected in these patients, echocardiographic assessment should be considered, because if there is valve insufficiency the cardiac function may deteriorate and cardiac surgery may be needed.

Acknowledgments

We are grateful to Dr J van der Meulen, cardiothoracic surgeon, for the surgical description and to Dr AC van der Wal, pathologist, for his pathology specimen evaluation. We thank Dr FM Westerweel, rheumatologist, for allowing us to report on her patient.

I E M Bultink, W F Lems, B A C Dijkmans, R M van Soesbergen

Department of Rheumatology, Slotervaart Hospital, Amsterdam, Jan van Breemen Institute, Amsterdam, and Vrije Universiteit Medical Centre, Amsterdam, The Netherlands

J Lindeman

Department of Pathology, Slotervaart Hospital, Amsterdam, The Netherlands

Correspondence to: Dr I E M Bultink, Department of Rheumatology, Slotervaart Hospital, Louwesweg 6 1066 EC, Amsterdam, The Netherlands; iem_bultink@hotmail.com

References

- 1 Lie JT. *Biopsy diagnosis in rheumatic diseases*. New York, Tokyo: Igaku-Shoin, 1997.
- 2 Cassidy JT, Petty RE. *Textbook of pediatric rheumatology*. 3rd ed. Philadelphia: Saunders, 1995:154-6.

- 3 Barron KS. Cardiovascular manifestations of connective tissue diseases. In: Garson A, Bricker JT, McNamara DG, eds. *The science and practice of paediatric cardiology*. Vol 2. Philadelphia: Lea and Febiger, 1990:1527-41.
- 4 Leak AM, Millar-Craig MW, Ansell BM. Aortic regurgitation in seropositive juvenile arthritis. *Ann Rheum Dis* 1981;40:229-34.
- 5 Kramer PH, Imboden JB, Waldman FM, Turley K, Ports TA. Severe aortic insufficiency in juvenile chronic arthritis. *Am J Med* 1983;74:1088-91.
- 6 Delgado EA, Petty RE, Malleon PN, Patterson MWH, D'Orsogna L, LeBlanc J. Aortic valve insufficiency and coronary artery narrowing in a child with polyarticular juvenile rheumatoid arthritis. *J Rheumatol* 1988;15:144-7.
- 7 Heyd J, Glaser J. Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. *Am J Med* 1990;89:123-4.
- 8 Keeley SB, Brewer PL, Burdette FM. Homograft root replacement for juvenile rheumatoid aortic valve incompetence. *Ann Thorac Surg* 1992;53:330-1.
- 9 Boris JR, Hollister JR, Tyson RW, Wolfe RR. Severe aortic regurgitation with mechanical prosthetic valve replacement in pauciarticular juvenile rheumatoid arthritis. *J Rheumatol* 1998;25:1211-14.

Polymyalgia rheumatica and pericardial tamponade

Polymyalgia rheumatica causes symmetrical stiffness in the neck, shoulder, and pelvic girdles, and affects middle aged and elderly people, with a higher incidence among women. A group of systemic, non-specific complaints such as weight loss, moderate fever, asthenia, and persistent high erythrocyte sedimentation rate are other clinical features.

The association of polymyalgia rheumatica and pericardial effusion has already been described in two cases.^{1,2}

A 73 year old woman was admitted for the evaluation of pericardial effusion and mild anaemia. Polymyalgia rheumatica was suspected because the patient had had asthenia, stiffness, and pain in the shoulders and hips for about a year before coming to hospital. She had also lost 5 kg in a few months. A few days before admission she had presented worsening dyspnoea.

An echocardiogram showed large pericardial effusion and initial findings of cardiac tamponade (right atrial and right ventricular diastolic collapse), so a pericardiocentesis was done: polymerase chain reaction tests in the pericardial fluid for *Mycobacterium tuberculosis* and cultures for aerobes and anaerobes were negative; tumoral cells were absent. Serological tests for antibodies to cytomegalovirus, herpes simplex and Epstein-Barr viruses, anti-smooth muscle, antinuclear, anti-DNA, and anti-extractable nuclear antigen antibodies were negative; Schirmer's test and the break-up time were also normal. The erythrocyte sedimentation rate (ESR) was 130 mm/1st h and C reactive protein (CRP) was 85 mg/l.

The patient was first treated with indometacin (50 mg twice a day) for a week, with no improvement, and then with low doses of prednisone (10 mg/day): the symptoms markedly improved and the ESR and CRP dropped to 27 mm/1st h and 12 mg/l, respectively, in a few weeks. An echocardiogram a month later was negative for pericardial effusion; ESR and CRP were also normal.

The patient has remained entirely well after a follow up of one year.

The presenting symptoms (girdles bilateral and symmetrical stiffness and pain) accompanied by systemic features (fatigue, weight loss, raised ESR) and the marked improvement after prednisone confirm the diagnosis of polymyalgia rheumatica.

As far as we know this is the first report of pericardial tamponade requiring pericardial drainage in this disease.

A Brucato, G Brambilla

Divisione Medica "Brera", Ospedale Niguarda Ca' Granda, Milan, Italy

Correspondence to: Dr G Brambilla, Divisione Medica "Brera", Via Mameli 46, 20129, Milan, Italy; bramgil@tiscalinet.it

References

- 1 Teira Cobo R, Zubero Sulibarria Z, Munoz Sanchez J, Santamaria Jauregi JM. Polymyalgia rheumatica and pericardial effusion. *Ann Med Interna* 1991;8:362-3.
- 2 Bohan A. Polymyalgia rheumatica and pericardial effusion. *Ann Intern Med* 1984;101:147.

Remission of Behçet's syndrome with TNF α blocking treatment

Goossens *et al* reported on a patient in whom a remission of Behçet's syndrome was induced with tumour necrosis factor (TNF) blocking treatment.¹ We would like to add our experience in a patient with Behçet's disease associated with rheumatoid arthritis (RA), treated with infliximab (Remicade).

A 47 year old male patient, born in Morocco, living in Israel, was diagnosed 14 years earlier with severe, progressive polyarthritis of hands, feet, and knees. Radiography showed articular bone erosions; rheumatoid factor was positive, with a high erythrocyte sedimentation rate and C reactive protein. In parallel, the patient reported recurrent buccal and genital ulcers two to three times a month with papulopustular skin lesions on the feet. HLA-B5 (51) was positive. There was no eye involvement. A diagnosis of Behçet's disease associated with erosive, seropositive RA was suggested. The patient was treated with sulfasalazine and colchicine without improvement; steroid treatment with auranofin was added. The disease was poorly controlled, with progressive erosions in hands, knees, and feet. Later, pulse steroids, methotrexate, azathioprine, and cyclosporin were added serially, either singly or in combination.

In subsequent years he became dependent on steroids and never achieved complete remission. In December 2000 the patient was admitted to hospital with severe active polyarthritis, flexion contractures of the elbows, and an especially swollen left knee with Baker's cyst and severe erosive disease. The patient additionally had buccal and penile ulcers. Because of the lack of response to conventional treatment we decided to treat him with infliximab (Remicade; Schering), a chimeric IgG monoclonal antibody directed against TNF. He received 300 mg intravenously (3 mg/kg) at intervals of two weeks, six weeks, and then every eight weeks. Two weeks after the first infusion the ulcers of mouth, penis, and other skin lesions were already considerably smaller and later disappeared. The polyarthritis improved considerably, except for the left knee, which required total replacement. Infliximab was given with continued colchicine and azathioprine. Our case, as in Goossens' report, suggests that infliximab may have a beneficial therapeutic effect in mucoserosal and cutaneous lesions as well as

synovitis in Behçet's disease, in our case in association with RA.

Controlled studies will be needed to assess adequately the full effect of TNF antagonists in Behçet's disease.

M Rozenbaum, I Rosner, E Portnoy

Department of Rheumatology, Bnai Zion Medical Centre, Technion Faculty of Medicine, Haifa, Israel

Correspondence to: Dr Rosner;
rosner@tx.technion.ac.il

- 1 **Goossens PH**, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor a blocking therapy. *Ann Rheum Dis* 2001;60:637.

Fatigue and immune activity in Sjögren's syndrome

Despite major desiccation of mucous membranes in Sjögren's syndrome (SS), fatigue is often experienced by patients as the most disabling complaint.^{1,2} Unfortunately, there is no proper treatment available to combat the fatigue in SS. Beside a variety of somatic and non-somatic conditions,²⁻⁶ increased immune activity has been implicated as a cause of fatigue in autoimmune diseases.^{6,7} If responsible for fatigue in SS, it could serve as a treatment target. The purpose of this study was, therefore, to examine the relation between fatigue and immune variables in SS.

Thirty six consecutive patients with primary SS visiting our outpatient departments participated in this study. Two control groups were used: a group of 18 patients diagnosed with secondary SS, and a group of 34 non-medicated healthy controls. Diagnoses were based on the revised European criteria for the classification of SS.⁸ Control groups were matched for age and sex. Disease duration or treatment did not differ significantly between patients with primary and secondary SS. Patients with other chronic diseases were excluded from the study. The Dutch Fatigue Scale (DUFS) was used to quantify fatigue. This validated questionnaire poses nine questions about different aspects of fatigue (table 1).⁹ Because depression is frequently observed in SS,^{2,5} a standardised psychiatric questionnaire (SCL-90) was used to rule out this potential confounding variable for fatigue.¹⁰ Immunological activity was evaluated by assessing rheumatoid factor, antinuclear antibodies, presence of anti-SS-A and anti-SS-B, levels of immunoglobulins (IgG, IgM, and IgA), haemoglobin levels, leucocytes, thrombocytes, erythrocyte sedimentation rate, and C reactive protein (CRP). After preliminary analysis using correlation tests, the best model to explain fatigue was calculated by using multiple regression with forward selection (SPSS version 8.0). Independent Student *t* tests were used to compare the studied groups.

Fatigue was equally raised in patients with both primary and secondary SS, and differed significantly from that of healthy controls. Twenty one (58%) patients with primary SS scored "high" or "very high" out of the six categories for depression according to the SCL-90 criteria. These depression scores did not significantly differ from the scores in secondary SS patients. Further analysis showed that 79% of the fatigue in patients with primary SS could be explained by depression, total level of immunoglobulins, and thrombocyte counts ($p < 0.001$). Both depression and thrombocyte counts showed a significant positive correlation, whereas levels of immunoglobulins showed a negative correlation.

Though tempting as a treatment target, the immune and inflammatory variables failed to predict fatigue satisfactorily in primary SS. Levels of immunoglobulins showed, surprisingly, a significant negative correlation. Thrombocyte counts showed a significant positive correlation. Although increases in thrombocytes follow the acute phase reaction, no significant correlation between thrombocyte counts and CRP levels were found. A chance association between fatigue and thrombocyte counts as well as immunoglobulin levels seems thus possible. Therefore, the intriguing question whether immune or inflammatory activity is a causative factor of chronic fatigue in SS remains unravelled. Because no difference in fatigue was found between patients with primary and secondary SS, the presence of another autoimmune disease appears to have no additional effect on the amount of fatigue in SS. In agreement with findings of previous studies, a significant relation was found between the degree of fatigue and the level of depression in patients with primary SS.^{2,5} It is concluded that none of the laboratory variables reflecting immune activity predict fatigue satisfactorily in primary SS. Signs of depression, as present in most of the patients with primary SS, proved to be the most relevant cause of their exhausting fatigue. Therefore we recommend including a psychosomatic approach in the treatment of fatigue in primary SS.

H I Bax, T M Vriesendorp, C G M Kallenberg

Department of Clinical Immunology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

W W I Kalk

Department of Oral and Maxillofacial Surgery, University Hospital Groningen

Correspondence to: Dr W W I Kalk, Department of Oral and Maxillofacial Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; w.w.i.kalk@kchir.azg.nl

References

- 1 **Gudbjörnsson B**, Broman JE, Hetta J, Hällgren R. Sleep disturbances in patients with

primary Sjögren's syndrome. *Br J Rheumatol* 1993;32:1072-6.

- 2 **Barendregt PJ**, Visser MRM, Smets EMA, Tulen JHM, van den Meiracker AH, Boomsma F, *et al*. Fatigue in primary Sjögren's syndrome. *Ann Rheum Dis* 1998;57:291-5.
- 3 **Flescher E**, Talal N. Do viruses contribute to the development of Sjögren's syndrome? *Am J Med* 1991;90:283-5.
- 4 **Alexander EL**, Kumar AJ, Kozachuk WE. The chronic fatigue syndrome controversy [letter]. *Ann Intern Med* 1992;117:343-4.
- 5 **Bierrum K**, Prause JU. Primary Sjögren's syndrome: a subjective description of the disease. *Clin Exp Rheumatol* 1990;8:283-8.
- 6 **Asim M**, Turney JH. The female patient with fatigue and fatigue: don't forget Sjögren's syndrome. *Nephrol Dial Transplant* 1997;12:1516-17.
- 7 **Wysenbeek AJ**, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. *Br J Rheumatol* 1993;32:633-5.
- 8 **Vitali C**, Bombardieri S, Moutsopoulos HM, Coll J, Gerli F, Hatzon PY, *et al*. The European classification criteria for Sjögren's syndrome (SS): proposal for a modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROC) curve of the criteria performance [abstract]. *J Rheumatol* 1997;24(suppl 50):38.
- 9 **Tiesinga LJ**, Dassen TVN, Halfens RJG. DUFS and DEFS: development, reliability and validity of the Dutch Fatigue Scale and the Dutch Exertion Fatigue Scale. *Int J Nurs Stud* 1998;35:115-23.
- 10 **Derogatis LR**, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. *Psychopharmacol Bull* 1973;9:13-28.

BOOK REVIEW

Glucocorticoids

Eds N J Goulding, R J Flower. (Pp 216; DM240.) Basel: Birkhäuser, 2001. ISBN 3-7643-6059-3. (Milestones in drug therapy. Series editors M J Parnham, J Bruinvels.)

People are bound to think: Oh no! Is yet another book about drugs that we are using successfully every day really necessary? Well, the answer to this question is: Yes, it is! More than 50 years after the clinical introduction of these drugs, updates are necessary to establish *Milestones in drug therapy* (the title of the series published by Birkhäuser). Sometimes unnoticed by all who use glucocorticoids, new, not always spectacular, but still significant knowledge has been gained about these vital drugs and how they should be administered. The authors try to put this across in a readable form, which means that known information is recapitulated concisely and new information is included. A very good example are the chapters that deal with the basic mechanisms of action. However, the only real criticism also applies at this point: some comments are redundant and tighter editing would have improved individual contributions.

Renowned authors reflect upon the most important facets of treatment with glucocorticoids. These facets include the history as well as basic biology, the development of synthetic compounds, extensive discussions about the glucocorticoid receptor, the dynamics of cytokine and other gene regulations by glucocorticoids, the interrelationship between exogenous and endogenous steroids, and a clinical section which deals with the use of steroids in asthma, arthritis, and inflammatory bowel disease. Allan Munck, one of the

Table 1 Dutch Fatigue Scale.⁹ Each item is scored on a 1 to 4 point scale

1. Listlessness
2. Perceived need for additional energy to finish required tasks
3. Verbalisation of an unremitting and overwhelming lack of energy
4. Inability to restore energy, even after sleeping
5. Increase in rest requirements
6. Decreased libido
7. Inability to maintain usual routine
8. Impaired ability to concentrate
9. Decreased performance

wise men of steroid research, describes the history of the glucocorticoids graphically and in detail. He has enriched research in this field with significant contributions since the beginning of the 1960s and now looks back amusingly and expressively on the past decades. Luca Parente's contribution ranges from naturally occurring to synthetic glucocorticoids and their effects in the organism. The sections that deal with the desired anti-inflammatory/immunomodulatory effects and adverse reactions give a valuable overview.

A few chapters should be highlighted that are of particular interest for both rheumatologists and clinical immunologists. That on molecular and cellular aspects of cytokine regulation by glucocorticoids has been prepared very carefully from a didactic point of view. It not only describes T cell activation and the effect of glucocorticoids thereon, but also provides useful information for an understanding of the function and regulation of cytokines. It is recapitulated that the central therapeutic effects of glucocorticoids are ultimately the inhibition of the synthesis of interleukin 2 and interleukin 6; glucocorticoids influence the transcription of around 1% of all genes! However, they also have an influence on the translational and post-translational mechanisms by which proteins are synthesised, processed, and exported from cells. This fact applies, in particular, to the influence on cytokine metabolism. Just to mention a few key concepts: post-transcriptional, translational, and post-translational mechanisms; modulation of cytokine receptors; indirect effects that occur as a result of the extensive interactions among various cytokines.

The chapter written by John Kirwan is worth reading for the rheumatologist, as it deals with the clinical aspect of the systemic administration of glucocorticoids in chronic inflammatory arthritis (typified by rheumatoid arthritis (RA)), in vasculitic episodes typified by those in systemic lupus erythematosus, and in polymyalgia rheumatica and temporal arteritis. It is cleverly written, because it questions apparently known facts, especially taking the example of RA. The important very short term anti-inflammatory effects are accepted and are broadly exploited. But is the risk/benefit potential also positive for medium and long term treatment? Do the glucocorticoids perhaps have a much more fundamental influence on the development and progression of RA than previously thought? Is there a differentiated and even treatment-time-dependent influence on synovitis, on the one hand, and on radiological progression, on the other? Possible answers to these exciting questions will not be anticipated here. However, this chapter, in particular, can be recommended, broadening as it does our picture of reality that is sometimes restricted to standard viewpoints.

The non-expert in the field might have wished for a little more clarity occasionally in the illustrations. The references to the individual chapters take into account publications

up to and including the year 2000. Overall, this is a good example of how knowledge on established drugs such as the glucocorticoids can be clearly updated.

F Buttgerieit

FORTHCOMING EVENTS

Tenth Intensive Applied Epidemiology Course for Rheumatologists

11–15 Mar 2002; Manchester, UK
No previous experience in epidemiology is needed. The course is residential and limited to 25 places

Contact: Ms Lisa McClair, ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK
Tel: +44 (0)161 275 5993
Fax: +44 (0)161 275 5043
Email: Lisa@fs1.ser.man.ac.uk

OMERACT VI

11–14 Apr 2002; Brisbane, Queensland, Australia

Includes two modules: MRI and economics; and five workshops: patients' perceptions, imaging (healing), progressive systemic sclerosis, mean clinical important difference, and osteoarthritis

Contact: Conference Organisers Q2Q, 7 Swan Street, Old Isleworth, Middlesex TW7 6RJ, UK
Fax: +44 20 8569 9555
Email: q2q@q2q.co.uk

British Society for Rheumatology XIXth AGM

23–26 Apr 2002; Brighton, UK

Contact: BSR, 41 Eagle Street, London WC1R 4TL, UK
Website: www.rheumatology.org.uk

4th EULAR Sonography Course

25–28 April 2002; Madrid, Spain

The course is entitled "Practical use of musculoskeletal ultrasonography"

Contact: Esperanzo Naredo
Email: enaredo@eresmas.com
Website: www.eular.org/courses and www.sameint.it/eular

10th International Vasculitis and ANCA Workshop

25–28 Apr 2002; Cleveland, Ohio, USA

Contact: Debora J Bork, The Cleveland Clinic Foundation, Desk A50, Center for Vasculitis Care and Research, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Tel: 216 445 8533
Fax: 216 445 7569

Email: borkd@ccf.org
Website for registration and abstract submission: www.clevelandclinicmeded.com/courses/Vasculitis2002.asp

International Congress: New Trends in Osteoarthritis

9–11 May 2002; Milan, Italy

Contact: Organising Secretariat, O.I.C. S.r.l., Via Fatebenefratelli 19, 20121 Milan, Italy
Tel: +39 02 65 71 200
Fax: +39 02 65 71 270
Email: osteoarthritis@oic.it

IOF World Congress on Osteoporosis

10–14 May 2002; Lisbon, Portugal

Contact: IOF Secretariat, 71 cours Albert Thomas, F-69003 Lyon, France
Tel: +33 472 91 41 77
Fax: +33 472 36 90 52
Email: info@iofyon.org
Website: www.osteofound.org

5th European Conference on Systemic Lupus Erythematosus

26–30 May 2002; Athens, Greece

Chairman Professor HM Moutsopoulos
Secretariat: Amphitriton Congress Organising Bureau
Email: hmoutsop@med.uoa.gr
Email: congress@amphitriton.gr

Annual European Congress of Rheumatology

12–15 June 2002; Stockholm, Sweden

Contact: Fred Wyss, Executive Secretary EULAR, Witikonstrasse 15, CH-8032, Zurich, Switzerland
Tel: +41 1 383 9690
Fax: +41 1 383 9810
Email: eular@bluewin.ch
Website: www.eular.org

10th International Congress on Behçet's Disease

27–29 June 2002; Berlin, Germany

Under the auspices of the International Society for Behçet's Disease
Up to eight young investigator awards, each of \$500, will be awarded on the basis of abstracts submitted

Contact: Professor Ch C Zouboulis, Department of Dermatology, University Medical Centre Benjamin Franklin, The Free University of Berlin, Fabekstrasse 60–62, 14195 Berlin, Germany
Fax: 49 30 84456908

Email: zoubbere@zedat.fu-berlin.de
Website: www.userpages.fu-berlin.de/~zoubbere
ISBD website: www.behcet.ws

29th Scandinavian Congress of Rheumatology

15–18 Aug 2002; Tromsø, Norway

Contact: Hans Nossent, Department of Rheumatology, University Hospital Tromsø, Norway
Tel: 47 776 27294
Fax: 47 776 27258
Email: 29scr2002@rito.no or revhan@rito.no

Translational Research in Autoimmunity

21–22 Sep 2002; Pavia, Italy

Contact: Organising secretariat: eventi S.R.L., Corso Cavour, 18/20 - 27100 Pavia, Italy
Email: tra@e20pr.com
Website: www.e20pr.com
Congress website: www.medicine.ucsd.edu/albani/2001 meeting

Osteoarthritis Research Society International (OARSI) World Congress

22–25 Sep 2002; Sydney, Australia

Contact: Osteoarthritis Research Society International (OARSI), 2025 M Street, NW, Suite 800, Washington DC 20036, USA
Tel: +1 202 367 1177

Fax: +1 202 367 2177
Email: oarsi@oarsi.org
Website: www.oarsi.org

10th International Congress on Antiphospholipid Antibodies

29 Sep–3 Oct 2002; Sicily, Italy
Deadline for abstracts 1 April 2002
Contact: Secretariat, 10th International Congress on Antiphospholipid Antibodies, c/o Kenes International, PO Box 50006, Tel Aviv 61500, Israel
Tel: 972 3 5140018/9
Fax: 972 3 5140077 or 972 3 5172484
Email: aps@kenes.com
Website: www.kenes.com/aps

Third International Congress on Spondyloarthropathies

2–5 Oct 2002; Gent, Belgium
Topics covered will be:
• Innate immunity
• Genetics and HLA-B27
• Animal models and pathogenesis
• Clinical research and therapy
Deadline for abstract submission 31 March 2002
Contact: Organisation and secretariat, Medicongress, Waalpoel 28–34, B-9960 Assenede, Belgium
Tel: +32 9 344 39 59
Fax: +32 9 344 40 10
Email: congresses@medicongress.com
Website: www.medicongress.com

7th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases

14–17 Oct 2002; Nashville, Tennessee, USA
Contact: Lawrence J Marnett, Biochemistry Department, Vanderbilt University, School of Medicine, Nashville TN 37232-0146, USA
Tel: (615) 343 7329
Fax: (615) 343 7534
Website: www.eicosanoids.science.eayne.edu

66th American College of Rheumatology AGM

25–29 Oct 2002; New Orleans, USA
Contact: ACR, Ronald F Olejko, Director of Conferences and Meetings, 1800 Century Place, Suite 250, Atlanta, Georgia 30045–4300, USA
Tel: +1 404 633 3777
Fax: +1 404 633 1870
Email: acr@rheumatology.org
Website: www.rheumatology.org

Third International Meeting on Social and Economic Aspects of Osteoporosis and Osteoarthritis

7–9 November, 2002; Barcelona, Spain
Contact: Yolande Piette Communication, Boulevard Kleyer 108, 4000 Liège, Belgium
Tel: 32 4 254 12 25
Fax: 32 4 254 12 90
Email: ypc@compuserve.com

Certifying Examination in Pediatric Rheumatology

18 Nov 2002
Contact: American Board of Pediatrics, 111 Silver Cedar Court, Chapel Hill, NC 27514-1513, USA
Tel: 919 929 0461
Fax: 919 918 7114 or 919 929 9255
Website: www.abp.org

Future EULAR congresses

18–21 June 2003; EULAR 2003 Lisbon, Portugal
9–12 June 2004; EULAR 2004 Berlin, Germany
8–11 June 2005; EULAR 2005 Vienna, Austria
21–24 June 2006; EULAR 2006 Amsterdam, The Netherlands

If you have a burning desire to respond to a paper published in the *Annals of the Rheumatic Diseases*, why not make use of our "rapid response" option?

Log on to our website (www.annrheumdis.com), find the paper that interests you, and send your response via email by clicking on the "eLetters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eLetters" on our homepage.

The editors will decide as before whether also to publish it in a future paper issue.